Thumbnail Image
Publication

The future of EPAC-targeted therapies: agonism versus antagonism

Parnell, E.
; 
Palmer, Timothy M.
; 
Yarwood, S.J.
Publication Date
2015
End of Embargo
Supervisor
Keywords
Exchange protein activated by cAMP, EPAC, cAMP, Inflammation, Diabetes, Agonism, Antagonism
Rights
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
cb
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Life Sciences Publications
Show all metadata
Files
Thumbnail Image
TIPS2015.pdf
Adobe PDF, 2.16 MB
Additional title
Abstract
Pharmaceutical manipulation of cAMP levels exerts beneficial effects through the regulation of the exchange protein activated by cAMP (EPAC) and protein kinase A (PKA) signalling routes. Recent attention has turned to the specific regulation of EPAC isoforms (EPAC1 and EPAC2) as a more targeted approach to cAMP-based therapies. For example, EPAC2-selective agonists could promote insulin secretion from pancreatic β cells, whereas EPAC1-selective agonists may be useful in the treatment of vascular inflammation. By contrast, EPAC1 and EPAC2 antagonists could both be useful in the treatment of heart failure. Here we discuss whether the best way forward is to design EPAC-selective agonists or antagonists and the current strategies being used to develop isoform-selective, small-molecule regulators of EPAC1 and EPAC2 activity.
URI
http://hdl.handle.net/10454/7171
Version
Published version
Citation
Parnell E, Palmer TM and Yarwood SJ (2015) The future of EPAC-targeted therapies: agonism versus antagonism. Trends in Pharmacological Sciences. 36(4): 203-214.
Link to publisher’s version
Link to published version
Link to Version of Record
https://doi.org/10.1016/j.tips.2015.02.003
Type
Article
Qualification name
Notes